PEPTONIC medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

PEPTONIC medical şirketinin toplam hissedar öz sermayesi SEK76.5M ve toplam borcu SEK5.2M olup, bu da borç-öz sermaye oranını 6.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK89.8M ve SEK13.3M dir.

Anahtar bilgiler

6.7%

Borç/özkaynak oranı

SEK 5.16m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 8.70m
Eşitlik	SEK 76.49m
Toplam yükümlülükler	SEK 13.33m
Toplam varlıklar	SEK 89.81m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PMED 'nin kısa vadeli varlıkları ( SEK36.8M ) kısa vadeli yükümlülüklerini ( SEK13.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: PMED un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PMED şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: PMED şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 6.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PMED şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: PMED tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

PEPTONIC medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Peptonic Medical AB (publ) Strengthens U.S. Market Presence with Full-Scale Launch of VagiVital

PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

PEPTONIC medical AB (publ) to Report Q2, 2024 Results on Aug 13, 2024

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

PEPTONIC medical AB (publ) to Report Q1, 2024 Results on May 07, 2024

PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO

Peptonic Medical AB (Publ) Announces Patented Apoteket Offering in 293 Apoteket Stores

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023

District Court Rejects the Claim for A Corporate Fine and Acquits All in Insider Case Against Peptonic Medical AB (Publ)

PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million.

Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED).

Peptonic Medical AB (Publ) Announces the Application to Patent Its Intimate Cleaner in US to Be Approved on June 20, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.15 loss per share (vs kr0.39 loss in FY 2021)

High number of new and inexperienced directors

PEPTONIC medical AB (publ) Ongoing Applications for the Intimate Wash and for the Treatment of Fungal Infection Has Received Positive Statements from the International Review

Peptonic Medical AB (Publ) Announces Vagivital® Al Self-Test for Amniotic Fluid Leakage Detection Is Now Commercially Available for Sale in Its Own Online Store

Peptonic Medical's Ongoing Application for Vestibulitis Patent Receives Positive Opinion from the International Review

Second quarter 2022 earnings released: kr0.037 loss per share (vs kr0.064 loss in 2Q 2021)

High number of new and inexperienced directors

First quarter 2022 earnings released

No independent directors

Hans von Celsing, Leni Ekendahl, Marianne Östlund and Anna Tenstam Declines Re-Election to the Board of Directors of PEPTONIC medical AB (publ)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PEPTONIC medical AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Peptonic Medical Introduces the Vagivital Range of Products to the US Market

Third quarter 2021 earnings released

PEPTONIC Initiates Non-Exclusive Negotiations Regarding a Possible Acquisition of All Assets in CommonSense Ltd (Israel)

Second quarter 2021 earnings released: kr0.064 loss per share (vs kr0.051 loss in 2Q 2020)

Peptonic Medical Gets Approval to Start a Clinical Trial for the Treatment of Vaginal Fungal Infections with an Adapted Version of VagiVital AktivGel

Peptonic Medical AB (Publ) Announces Latest Clinical Study with Vagivita

Peptonic Medical (publ) to Launch New Innovative Intimate Care Range Under Lunette Brand, Bringing Special Nordic Ingredients Down There

First quarter 2021 earnings released

New 90-day low: kr1.55

PEPTONIC medical AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day low: kr1.60

Chief Financial Officer recently sold kr84k worth of stock

New 90-day low: kr1.68

Third quarter 2020 earnings released: kr0.041 loss per share

Peptonic to Launch the Self-Test Under the VagiVital® Brand

New 90-day low: kr1.98

Peptonic Medical AB Files Patent Application for the Treatment of Fungal Infections and Bacterial Vaginosis

New 90-day high - kr2.38

Earnings released

New 90-day high - kr2.24

PEPTONIC medical AB (publ) (NGM:PMED) exercised the option to acquire remaining 26.67% stake in Lune Group Oy Ltd for €1.2 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin